Product Reports Resources Pricing Login Book a demo
Christoph Lengauer
Person deep dive

Christoph Lengauer

#77 2026 Strebulaev–Jackson Venture Ranking, emerging firms

Christoph Lengauer is a cancer biologist and a founder and chief scientific officer of Curie.Bio, a Boston seed and Series A biotech firm. As a partner at Third Rock Ventures he co-founded Thrive Earlier Detection, bought by Exact Sciences, and Celsius Therapeutics, bought by AbbVie.

Founded
Curie.Bio, Moma Therapeutics, Thrive Earlier Detection +1 more
Education
Johns Hopkins University, University of Heidelberg, Paris Lodron University of Salzburg

Track record

Investments Christoph Lengauer is best known for, with what became of them.

Curie.Bio

FirmCurie.Bio
Founded2022
Based inBoston
Funds$1B under management for seed and Series A rounds (company LinkedIn page)
FocusSeed and Series A drug discovery companies, including spinouts

Career

  1. 1994Joined Bert Vogelstein's lab at Johns Hopkins, where he later became an associate professor.
  2. 2006Left Johns Hopkins for Novartis, where he ran an oncology drug discovery unit.
  3. Became global head of oncology drug discovery and preclinical development at Sanofi.
  4. Served as chief scientific officer of Blueprint Medicines.
  5. Joined Third Rock Ventures as a partner and co-founded Thrive Earlier Detection, Celsius Therapeutics and Moma Therapeutics.
  6. 2020Exact Sciences agreed to buy Thrive and Base Genomics for a combined $2.56B.
  7. 2022Co-founded Curie.Bio in Boston and became its chief scientific officer.

Sources: Dealroom — Christoph Lengauer · Dealroom — Curie.Bio · Wikipedia — Exact Sciences (Thrive acquisition) · Curie.Bio — Our team. Rank: 2026 Strebulaev–Jackson Venture Ranking.

Companies founded

Currently

Active roles, board seats and partnerships.

raceforlife.org
Board Member · 2023 – present
Johns Hopkins University
Adjunct Associate Professor · 1994 – present

Work history

Past roles by Dealroom records.

MKT4INTEL
Associate · 2018 – 2019
Third Rock Ventures
Partner · Venture Partner · 2016 – 2022
→
Blueprint Medicines
CSO · VP · 2012 – 2021
$9.1B valuation (2025)Unicorn
→
Sanofi Aventis
Global Head of Oncology Drug discovery · Preclinical development. · Vice President and Global Head of Oncology Drug discovery and Preclinical development. · VP · 2008 – 2012
Novartis
Unit Head - Oncology Drug Discovery · 2005 – 2008
$303B valuation (2026)
→
Novartis Institutes
Executive Director · Executive Director & Senior Unit Head Oncology Discovery · Senior Unit Head Oncology Discovery

Education

Johns Hopkins University
Biology · 1994 – 1996
University of Heidelberg
PhD · Biology · 1988 – 1992
Paris Lodron University of Salzburg
1985 – 1989
← All people